Cytognomix has agreed to provide hybridization enrichment products to the Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine at the Istituto Nazionale dei Tumori (INT), Fondazione IRCCS-Milan for sequencing of genes associated inherited neoplastic disease. The company’s scProbe design technology was selected by the INT because it provides the highest depth and breadth of sequence coverage for sequencing of complete cancer genes on the market today.
Monthly Archives: December 2013
December 10, 2013. New patent on detecting biological exposure to radiation
US Patent 8,605,981, titled “Centromere detector and method for determining radiation exposure from chromosome abnormalities,” has been issued to Peter K. Rogan, Joan H. Knoll, Jagath Samarabandu, and Akila Subasinghe. The patent is assigned to Cytognomix. The inventors have developed Automated Dicentric Chromosome Identifier (ADCI) software based on this technology. The present version of ADCI runs threaded on a multi-CPU desktop PC, and has been parallelized for high throughput processing on a number of multi-core systems, including IBM’s BlueGene/Q. We have achieved high throughput of automated chromosome-based biodosimetry analysis, completing processing of images from 1000 samples in an hour with this hardware platform.
January 20, 2013. Canadian Breast Cancer Foundation highlights Early Breast Cancer Detection project based on Cytognomix technology
The Canadian Breast Cancer Foundation has recognized our progress in developing novel next generation DNA sequencing and companion bioinformatic analysis technologies for early detection of breast cancer.
See their profile at: Canadian Breast Cancer Foundation article on Dr. Peter Rogan.
Update January 20, 2013. CBCF has published a new full profile of our project.
December 5, 2013. Breast Cancer Society of Canada Blog profiles our research
Stephanie Dorman published a method that improves the accuracy of a test commonly used in the genetic analysis of many types of cancers (Dorman et. al. Expanding probe repertoire and improving reproducibility in human genomic hybridization, Nucleic Acids Research, 41:e81, 2013). This technology was developed, supported and patented by Cytognomix.
See: The Breast Cancer Society of Canada profiles Cytognomix supported research